Ken Kato

29.6k total citations · 7 hit papers
507 papers, 13.3k citations indexed

About

Ken Kato is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Ken Kato has authored 507 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Pulmonary and Respiratory Medicine, 261 papers in Surgery and 256 papers in Oncology. Recurrent topics in Ken Kato's work include Esophageal Cancer Research and Treatment (218 papers), Gastric Cancer Management and Outcomes (211 papers) and Cancer Immunotherapy and Biomarkers (109 papers). Ken Kato is often cited by papers focused on Esophageal Cancer Research and Treatment (218 papers), Gastric Cancer Management and Outcomes (211 papers) and Cancer Immunotherapy and Biomarkers (109 papers). Ken Kato collaborates with scholars based in Japan, United States and United Kingdom. Ken Kato's co-authors include Yasuhide Yamada, Yuko Kitagawa, Yasuhiro Shimada, Tetsuya Hamaguchi, Satoru Iwasa, Takashi Kojima, Kei Muro, Yuichiro� Doki, Hiroyuki Daiko and Yasuo Hamamoto and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ken Kato

470 papers receiving 13.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Ken Kato, Keisho Chìn et al. profile →
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

2018 400 citations Yuko Kitagawa, Ken Kato et al. Esophagus profile →
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

2018 367 citations Yuko Kitagawa, Ken Kato et al. Esophagus profile →
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

2018 362 citations Manish A. Shah, Takashi Kojima et al. profile →
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 292 citations Toshihiro Kudo, Yasuo Hamamoto et al. profile →
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

2018 228 citations Narikazu Boku, Ken Kato et al. Annals of Oncology profile →
A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

2022 119 citations Ken Kato, Yoshinori Ito et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ken Kato

Since Specialization

Citations

This map shows the geographic impact of Ken Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Kato more than expected).

Fields of papers citing papers by Ken Kato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Kato. The network helps show where Ken Kato may publish in the future.

Co-authorship network of co-authors of Ken Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Kato. A scholar is included among the top collaborators of Ken Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Kato. Ken Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing 2025 ·Japanese Journal of Clinical Oncology ·(unknown), (unknown), Tatsuya Yoshida, Kuniko Sunami, (unknown), Takafumi Koyama, Kan Yonemori, Takuji Okusaka, Ken Kato, Yuichiro Ohe, Yasushi Yatabe, Noboru Yamamoto	1
2	First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305 2025 ·Advances in Therapy ·Markus Moehler, Do‐Youn Oh, Ken Kato, Hendrik‐Tobias Arkenau, Josep Tabernero, Keun‐Wook Lee, Sun Young Rha, Hidekazu Hirano, David R. Spigel, Kensei Yamaguchi, Lucjan Wyrwicz, Umut Dişel, Roberto Pazo-Cid, Lorenzo Fornaro, Yaling Xu, Tao Sheng, Silu Yang, (unknown), Marcia Cruz‐Correa, Rui‐Hua Xu	2
3	Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin 2024 ·In Vivo ·(unknown), Shun Yamamoto, Yoshitaka Honma, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Akihito Nagahara, Ken Kato	2
4	395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 2024 ·Annals of Oncology ·(unknown), Jianming Xu, Ken Kato, (unknown), Yongqian Shu, (unknown), (unknown), Lucjan Wyrwicz, David Tougeron, Karel Geboes, (unknown), Roberto Pazo-Cid, Aziz Zaanan, (unknown), Hongqian Wu, Jingwen Shi, (unknown), Sijia Yan, Harry H. Yoon	1
5	LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma 2024 ·Future Oncology ·Jong‐Mu Sun, Antoine Adenis, Peter C. Enzinger, Manish A. Shah, Ken Kato, Jaafar Bennouna, Toshihiko Doi, Natalyn Hawk, Li Yu, Sukrut Shah, Pooja Bhagia, Lin Shen	2
6	Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Jun Sato, Yuta Maruki, (unknown), Kenjiro Namikawa, Kazuki Sudo, Yoshitaka Honma, Hironobu Hashimoto, Naoya Yamazaki, Takuji Okusaka, Kan Yonemori, Noboru Yamamoto, (unknown), Ken Kato	2
7	Identification of barriers to implementation of precision oncology in patients with rare cancers 2024 ·Cancer Science ·(unknown), Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, (unknown), Kayoko Tao, (unknown), Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto	2
8	Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab 2023 ·Cancer Medicine ·(unknown), Satoru Iwasa, Kengo Nagashima, (unknown), Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku	2
9	1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213 2023 ·Annals of Oncology ·(unknown), Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, Takuji Okusaka, Narikazu Boku, Ken Kato, Gakuto Ogawa, Y. Sano, Hiroshi Imaoka, Satoshi Kobayashi, Takeshi Terashima, Masafumi Ikeda, Naohiro Okano, Kensei Yamaguchi, Tosiya Sato, Nobumasa Mizuno, Yuko Kitagawa, Masanori Terashima, Makoto Ueno	1
10	Protocol digest of a randomized controlled Phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced oesophageal squamous cell carcinoma with no pathological complete response after neoadjuvant chemotherapy followed by curative esophagectomy: Japan Clinical Oncology Group study JCOG2206 (SUNRISE Trial) 2023 ·Japanese Journal of Clinical Oncology ·Ryosuke Kita, Satoru Matsuda, Motoo Nomura, Ryunosuke Machida, Keita Sasaki, Ken Kato, Rei Goto, Takashi Yoshioka, Shun Yamamoto, Takahiro Tsushima, Haruhiko Fukuda, Hiroya Takeuchi, Yuko Kitagawa	7
11	Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma 2022 ·Auris Nasus Larynx ·Go Omura, Yoshitaka Honma, Yoshifumi Matsumoto, Takeshi Shinozaki, (unknown), (unknown), Toshihiko Sakai, (unknown), (unknown), (unknown), Ken Kato, Seiichi Yoshimoto	20
12	Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303) 2022 ·Esophagus ·Takashi Kojima, Ken Kato, Hiroki Hara, Shunji Takahashi, Kei Muro, Tomohiro Nishina, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Toshihiko Doi	17
13	Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807 2022 ·Esophagus ·Takashi Ura, Shuichi Hironaka, Yasuhiro Tsubosa, Junki Mizusawa, Ken Kato, Takahiro Tsushima, (unknown), Keisho Chìn, Akihisa Tomori, Tatsuya Okuno, Hisayuki Matsushita, Takashi Kojima, Yuichiro� Doki, Hitoshi Kusaba, Kazumasa Fujitani, (unknown), Yuko Kitagawa	6
14	Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer 2020 ·Cancer Science ·Ken Kato, Yuichiro� Doki, Takashi Ura, Yasuo Hamamoto, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Toshihiro Kudo, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuko Kitagawa	23
15	The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909 2020 ·Esophagus ·Shuichi Hironaka, Azusa Komori, Ryunosuke Machida, Yoshinori Ito, Hiroya Takeuchi, Gakuto Ogawa, Ken Kato, Masakatsu Onozawa, Keiko Minashi, Tomonori Yano, Kenichi Nakamura, Takahiro Tsushima, Hiroki Hara, Isao Nozaki, Takashi Ura, Keisho Chìn, Haruhiko Fukuda, Yuko Kitagawa	8
16	Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer 2019 ·Clinical Cancer Research ·Fumihiko Urabe, Juntaro Matsuzaki, Yusuke Yamamoto, Takahiro Kimura, Tomohiko Hara, Makiko Ichikawa, Satoko Takizawa, Yoshiaki Aoki, Shumpei Niida, Hiromi Sakamoto, Ken Kato, Shin Egawa, Hiroyuki Fujimoto, Takahiro Ochiya	87
17	Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer 2018 ·Clinical Cancer Research ·Sho Shiino, Juntaro Matsuzaki, Akihiko Shimomura, Junpei Kawauchi, Satoko Takizawa, Hiromi Sakamoto, Yoshiaki Aoki, Masayuki Yoshida, Kenji Tamura, Ken Kato, Takayuki Kinoshita, Yuko Kitagawa, Takahiro Ochiya	47
18	Whey Protein-hydrolyzed Peptides Diminish Hepatic Lipid Levels in Rats Consuming High-sucrose Diets 2016 ·Food Science and Technology Research ·(unknown), Hiroyuki Sakakibara, (unknown), Keisuke Kimura, (unknown), Takayuki Nara, Ken Kato, Masanobu Sakono	9
19	Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients 2016 ·Cancer Immunology Research ·Kohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Kazunori Aoki, Nobuyoshi Hiraoka, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Yuji Heike, Tetsuya Hamaguchi	54
20	Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. 2012 ·PubMed ·Takayuki Yoshino, Kentaro Yamazaki, Tetsuya Hamaguchi, Yasuhiro Shimada, Ken Kato, Hirofumi Yasui, Narikazu Boku, María José Lechuga, Tomoko Hirohashi, Atsushi Shibata, Satoshi Hashigaki, (unknown), Atsushi Ohtsu	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact